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Abstract: Extracellular ATP mediates proinflammatory and antiproliferative effects via activation
of P2 nucleotide receptors. In contrast, its metabolite, the nucleoside adenosine, is strongly im-
munosuppressive and enhances tumor proliferation and metastasis. The conversion of ATP to
adenosine is catalyzed by ectonucleotidases, which are expressed on immune cells and typically up-
regulated on tumor cells. In the present study, we identified sulfopolysaccharides from brown
and red sea algae to act as potent dual inhibitors of the main ATP-hydrolyzing ectoenzymes,
ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) and ecto-nucleoside triphosphate
diphosphohydrolase-1 (NTPDase1, CD39), showing nano- to picomolar potency and displaying a
non-competitive mechanism of inhibition. We showed that one of the sulfopolysaccharides tested as
a representative example reduced adenosine formation at the surface of the human glioblastoma cell
line U87 in a concentration-dependent manner. These natural products represent the most potent
inhibitors of extracellular ATP hydrolysis known to date and have potential as novel therapeutics for
the immunotherapy of cancer.
Keywords: adenosine; CD39; ectonucleotidase inhibitors; fucoidan; immuno-oncology; NPP1; NTP-
Dase1; macroalgae constituents; sulfated polysaccharides
1. Introduction
Nucleosides and nucleotides, e.g., adenosine, ATP and ADP, act as extracellular sig-
naling molecules activating P1 (adenosine) or P2 (nucleotide) receptors [1–5]. Adenosine
receptors are G protein-coupled receptors (GPCRs), while P2 receptors are further subdi-
vided into P2Y (GPCRs) and P2X (ligand-gated ion channel) receptor subtypes. Nucleotides
can be converted by a cascade of ectonucleotidases to adenosine (see Figure 1). Many tumor
cells overexpress ectonucleotidases that metabolize proinflammatory ATP to adenosine,
which exerts immunosuppressive, angiogenic, prometastatic and tumor growth promoting
activities [5]. Ectonucleotidase inhibition has therefore been proposed as a novel approach
for cancer immunotherapy [6,7]. Different classes of ectonucleotidases exist including
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nucleotide pyrophosphatase/phosphodiesterases (NPPs), nucleoside triphosphate diphos-
phohydrolases (NTPDases), alkaline phosphatases (AP) and ecto-5′-nucleotidase (cluster
of differentiation 73 (CD73)). The NPP family consists of seven structurally related ectoen-
zymes (NPP1-NPP7), four of which are known to hydrolyze extracellular nucleotides [1,2,8].
NPP1 (CD203a, also known as PC-1 (plasma cell antigen-1), EC 3.1.4.1) and NPP3 catalyze
the hydrolysis of a variety of nucleotides including nucleoside triphosphates (e.g., ATP and
UTP), dinucleotide polyphosphates (e.g., Ap3A and Ap4A), cyclic dinucleotides (e.g.,
2′,3′′-cGAMP) and nucleotide sugars (e.g., UDP-glucose and ADP-ribose) [9–12], NPP1
preferentially hydrolyzes ATP into AMP and PPi. NPP4 was reported to hydrolyze the
physiological dinucleotides Ap3A and Ap4A, while ATP hydrolysis by this enzyme is negli-
gible [11]. NPP5 has recently been reported to hydrolyze nicotinamide adenine dinucleotide
(NAD+) [13]. Other members of the NPP family, i.e., NPP2 (autotaxin), NPP6 and NPP7
(alkaline sphingomyelinase) act as phospholipases [8]. The NTPDase family comprises
eight members (NTPDase 1-8), NTPDase1 (CD39, EC 3.6.1.5) being the most prominent
member of this family in blood vessels and at the surface of leukocytes. They catalyze the
hydrolysis of extracellular nucleoside tri- and diphosphates by cleaving off phosphate [8].
Ecto-5′-nucleotidase (CD73) hydrolyzes nucleoside monophosphates, e.g., AMP, to the
corresponding nucleoside, e.g., adenosine. Thus, proinflammatory, antiproliferative ATP
can be converted by subsequent action of NPP1 or CD39 and CD73 to immunosuppressive
adenosine (Figure 1), which then accumulates in the tumor environment leading to immune
escape of the tumor.
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Recently, there has been an enormous interest in identifying and developing ectonu-
cleotidase inhibitors, antibodies and small molecules, as novel cancer immunotherapeu-
tics [4,6,7]. 
Several antibodies and small molecules have been developed for blocking the AMP-
hydrolyzing, adenosine-producing ectoenzyme CD73, and the first drugs are currently 
evaluated in clinical trials for the immunotherapy of cancer to prevent the formation of 
immunosuppressive adenosine [14]. The blockade of enzymes that hydrolyze extracellu-
lar ATP to AMP could be even more efficient since it would lead to the accumulation of 
antiproliferative ATP in addition to preventing the formation of immunosuppressive 
adenosine due to the depletion of AMP as a CD73 substrate. 
On the other hand, ATP, which acts on different subtypes of P2Y (G protein-coupled) 
and P2X (ligand-gated ion channel) receptors that are activated by different ATP concen-
trations depending on the receptor subtype, can also display proinflammatory effects 
since they belong to the danger-associated molecular patterns (DAMPs) [15]. In these 
cases, inhibition of ATP hydrolysis may result in proinflammatory effects. 
So far, only moderately potent and/or non-selective NPP1 and CD39 inhibitors have 
been described, which can be divided into nucleotides and non-nucleotides. N6-Diethyl-
β,γ-dibromomethylene-ATP (ARL 67156, 1) is a weak dual CD39/CD73 inhibitor with low 
metabolic stability [16,17]. Several other negatively charged compound classes including 
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Recently, there has been an enormous interest in identifying and developing ectonu-
cleotidase inhibitors, antibodies and small molecules, as novel ca cer immunotherapeu-
tics [4,6,7].
Several antibodies and small molecules have been developed for blocking the AMP-
hydrolyzing, adenosine-producing ectoenzyme CD73, and the first drugs are currently
evaluated in clinical trials for the immunotherapy of cancer to prevent the formation of
immunosuppressive adenosine [14]. The blockade of enzymes that hydrolyze extracellular
ATP to AMP could be even more efficient since it would lead to the accumulation of
antiproliferative ATP in addition to preventing the formation of immunosuppressive
adenosine due to the depletion of AMP as a CD73 substrate.
On the other hand, ATP, which acts on different subtypes of P2Y (G protein-coupled)
and P2X (ligand-gated ion channel) receptors that are activated by different ATP concentra-
tions depending on the receptor subtype, can also display proinflammatory effects since
they belong to the danger-associated molecular patterns (DAMPs) [15]. In these cases,
inhibition of ATP hydrolysis may result in proinflammatory effects.
So far, only moderately potent and/or non-selective NPP1 and CD39 inhibitors have
been described, which can be divided into nucleotides and non-nucleotides. N6-Diethyl-
β,γ-dibromomethylene-ATP (ARL 67156, 1) is a weak dual CD39/CD73 inhibitor with
low metabolic stability [16,17]. Several other negatively charged compound classes in-
cluding (poly)sulfonates such as suramin (2) and sulfoanthraquinones [18–20], and poly-
oxometalates (POMs), e.g., [TiW11CoO40]8− (3) and [Co4(H2O)2(PW9O34)2]10− (4) [21,22],
were found to inhibit CD39 and/or NPP1. A selection of the most potent NPP1 and CD39
inhibitors is depicted in Figure 2.
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Sulfated polysaccharides from sea algae, in particular fucoidans present in brown
algae, e.g., from Sargassum polycystum [23], have been reported to possess antitumor activity
in vitro and in vivo [24–27]. These natural products were shown to inhibit cell growth
directly, e.g., by inducing apoptosis, and, in addition, to activate the immune system in its
fight against cancer [28–30]. Their molecular mechanism of action is not fully understood
at present, and the molecular targets are largely unknown [31]. This prompted us to study
exemplary polysaccharides from red and brown algae, which are negatively charged like
reported ectonucleotidase inhibitors (Figure 2), for inhibitory effects on these enzymes.
2. Results and Discussion
Four sulfated polysaccharides 5–8 (Table 1), extracted from different algae species,
were investigated in the present study as potential inhibitors of ectonucleotidases. Com-
pound 5 and 8 represent sulfated xylogalactans from red algae, compounds 6 and 7 are
brown algae-derived fucoidans. They were extracted, purified and chemically character-
ized as previously described [32–34]. The chemical characteristics of the used batches are
shown in Tables 1 and 2.
Table 1. Basic characteristics of investigated sulfated algae polysaccharides.




Sulfation a Molar Mass (kDa)
b Proteins (%) c Uronic Acids (%) d
5 Xylogal ctan Delesseria sanguinea 0.65 ± 0.02 214 ± 28 7.24 ±0.07 3.96 ± 0.54
6 Fucoidan Saccharina latissima 0.52 ± 0.01 534 ± 11 8.08 ±0.09 7.42 ± 0.18
7 Fucoidan Fucus vesiculosus 0.59 ± 0.01 38 ± 1 7.07 ± 1.59 0.27 ± 0.27
8 Xylogalactan Coccotylus truncatus 0.52 ± 0.01 128 ± 4 3.74 ±1.29 9.50 ± 0.23
a Average number of sulfate groups per monosaccharide related to the total glycan content; it was calculated by means of the SO3Na,
which was derived from % sulfur content determined by elemental analysis (mean ± SD, n = 2). b Mean weight average molar mass,
determined by SEC-MALS-RI, mean ± SD (mean ± SD, n = 3). c The content of protein was calculated by elemental analysis (% nitrogen)
(mean ± SD, n = 2). d Determined according to the method of Blumenkrantz et al. [35] and Filisetti-Cozzi et al. [36] (mean ± SD, n = 2 × 2).
Table 2. Composition of investigated sulfated algae polysaccharides.a











5 Xylogalactan 0.0 75.3 16.1 2.5 6.1 0.0
6 Fucoidan 53.4 13.6 6.7 5.4 19.8 1.3
7 Fucoidan 83.1 7.3 6.5 2.0 0.4 0.7
8 Xylogalactan 0.0 87.6 3.8 6.7 2.0 0.0
a Determined according to the method of Blakeney et al. [37].
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We initially tested the effects of the compounds at a concentration of 20,000 ng/mL
on the most prominent ectonucleotidase families, NPPs (NPP1, 3, 4 and 5), NTPDases
(NTPDase1, 2, 3 and 8) and CD73 (see Figure 3).
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1 ARL 67156 973 ± 239 [14] a 4410 ± 3,530 [14] b
2 Suramin 780 ± 81 [38] b 300,000 ± 100 [18] b
3 PSB- OM142 690 ± 4 [22] b 3.8 ± 1.40 [2 ] c
4 PSB-POM141 1.46 ± 0.01 [22] b 173 ± 4 [22] c
Sulfated algae sac harides
5 Delesseria sanguinea 0.0517 ± 0.0016
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1.72 ± 0.00 d
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Experimental Section.
Some of the investigated sulfated polysaccharides from sea algae were discovered
to be the most potent NPP1 and CD39 inhibitors described to date displaying nano- to
subnanomolar potencies. The potency calculated in nmol/L (nM) did not depend on
the molecular weight. Sulfated polysaccharide 5 (MW 214 kDa) was almost 3-fold more
potent at NPP1 as compared to compound 6 (MW 534 kDa). Compound 5 showed 33-
fold selectivity for NPP1 over CD39, while 6 was about equipotent. Compounds 7 and 8
displayed somewhat lower potency combined with moderate selectivity for NPP1 versus
CD39 (see Figure 5). Compound 5 is an extremely potent NPP1 inhibitor with picomolar
inhibitory potency at NPP1 (Ki 0.0517 nM) showing ancillary CD39 inhibition (Ki 1.72 nM),
but being highly selective versus all other investigated ectonucleotidases. Sulfated polysac-
charide 6 is about equipotent at both NPP1 and CD39, and can be envisaged as a dual
NPP1/CD39 inhibitor. Such dual activity could be a big advantage in cancer therapy since
both ATP-hydrolyzing enzymes may be upregulated and constitute redundant pathways
for nucleotide degradation.
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Figure 5. pIC50 (−log IC50) values of compounds 5–8 at the ectonucleotidases NPP1 and CD39 are
shown. Error bars represent SD values. For IC50 values see Table 3.
Next, we studied the inhibition type for compound 7, the compound with the lowest
molecular weight, as a representative for this new class of ectonucleotidase inhibitors using
ATP as a substrate. Considering the size of the compounds (with molecular masses ranging
from 38 to 534 kDa) and based on their structures, we presumed an allosteric mechanism
of inhibition. The effect of inhibitor 7 on the kinetics of NPP1 and CD39 was investigated.
In both cases, the Michaelis–Menten plots (Figure 6A,C) clearly showed a decrease in
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Vmax in the presence of the inhibitor, which is indicative of a non-competitive or mixed
type of inhibition. Moreover, the apparent Km values are increased at higher inhibitor
concentrations. The Lineweaver–Burk plot [39] confirmed a non-competitive/mixed type
of inhibition (Figure 6B,D) at both enzymes, NPP1 and CD39.
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the SLC29 transporter family [45], and erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) 
was present to inhibit metabolism of adenosine to inosine [46]. Cells treated with ATP, 
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trophoresis coupled to UV detection. The results clearly showed a concentration-depend-
ent inhibition of adenosine formation by sulfopolysaccharide 7 in U87 glioma cells, which 
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Fi ally, we inv stigated compound 7 in a m re complex cellular system. The human
glioblastoma cell line U87 had previously been shown to express NPP1 and CD73 [40–43],
but only negligible amou ts of CD39 [44]. These enzymes are known to convert ATP to
adenosine in a sequential reaction cascade (see Figure 1). Therefore, we used this cancer
cell line to determine the hydrolysis of extracellular ATP, added to the cells, resulting in
the formation of adenosine, which is known to produce antiproliferative, antiangiogenic,
metastasis-promoting and immunosuppressive effects when released into the tumor mi-
croenvironment. Dipyridamole was added to block the cellular uptake of adenosine via
the SLC29 transporter family [45], and erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) was
present to inhibit metabolism of adenosine to inosine [46]. Cells treated with ATP, dipyri-
damole and EHNA were studied in the absence an in the presence of sulfopolysaccharide
7, and extracellular adenosine accumulation was quantified by capillary electrophoresis
c upled to UV detection. The results clearly showed a concentration-d pendent inhibition
of adenosine formation by sulfopolysaccharide 7 in U87 glioma cells, which is assumed
to be due o the blockade of NPP1 by i hibitor 7. Thes data confirmed the s rong in-
hibitory activity of ectonucl otidase inhibitor 7 (a a r presentative of the hemical class of
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sulfopolysaccharides) on the formation of extracellular adenosine from ATP by a human
glioblastoma cell line (Figure 7).
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3. Materials and Methods
The s polysac harides 5–8 were isolated from the two brown algae Saccharina latissima
(Laminari les, Laminariaceae) (North Atlantic Faroe Island) Fucus vesiculos s (Fu-
cales, Fuca ea ) and the two red algae Delesseria l , elesseriaceae)
and Co cotylus truncatus (Gigartinales, Phyllophoraceae) (both collected in the sublittoral
habitat of the large artificial reef near ienhagen (Baltic Sea, er any). They were ex-
tracted, purified and che ically characterized as previously described [32–34], hereby
compound 7, fucoidan from Fucus vesiculosus was purchased fro Sigma-Aldrich, catalog
No. F5631, Lot No SLBC4004 V). In short: the pulverized algal material was defatted
with Soxhlet extraction (99% v/v ethanol). The main extraction was performed with dem-
ineralized water at 85 ◦C for 8 h (compound 5) and aqueous 2% CaCl2 at 85 ◦C for 2 h
(compounds 6 and 8) (reflux condition). The supernatant was evaporated and precipitated
with ethanol (final concentration 60% v/v) at 4 ◦C. Further steps involved centrifugation,
dissolving in demineralized water, dialysis and lyophilization. The analyzed chemical
parameters included sulfate content and degree of sulfation, weight average molar mass,
monosaccharide composition, contents of protein and uronic acids.
3.1. Chemicals
Nucleotides (AMP, ADP, ATP and cAMP), nucleosides (adenosine, inosine and uri-
dine), dipyridamole, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), disodium hydrogen-
phosphate and sodium dodecyl sulfate were purchased from Merck KGaA (Darmstadt, Ger-
many). Sodium chloride, potassium chloride, potassium dihydrogen phosphate, sodium
hydrogencarbonate, D-glucose, N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid]
(HEPES), calcium chloride and magnesium sulfate were purchased from PAN Biotech
GmbH (Aidenbach, Germany). Dulbecco’s modified Eagle medium, fetal calf serum (FCS),
penicillin/streptomycin (P/S) and L-glutamine were also from PAN Biotech GmbH.
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3.2. NPP1 Assay
Recombinant soluble human NPP1 was obtained as previously described [22]. Com-
pounds 5–8 were tested as inhibitors of human NPP1 at a concentration of 20,000 ng/mL
vs. ATP (400 µM) as a substrate. Subsequent concentration–inhibition curves were per-
formed using several dilutions of the test compounds prepared in assay buffer (10 mM
N-cyclohexyl-2-aminoethanesulfonic acid (CHES), 2 mM CaCl2 and 1 mM MgCl2, pH 9.00).
The human NPP1, prepared as previously described [22], was diluted in the assay buffer,
and 0.224 µg of the enzyme were employed per vial. The mixture was incubated for 30 min
at 37 ◦C, and the reaction was terminated by heating at 90 ◦C for 5 min. After cooling
down on ice, analysis was carried out using capillary electrophoresis (CE). Positive and
negative controls were studied in parallel. Data collection and peak area analysis were
performed by the P/ACE MDQ software 32 KARAT obtained from Beckman Coulter
(Fullerton, CA, USA). A polyacrylamide-coated capillary was used (30 cm (20 cm effective
length) × 50 µm (id) × 360 µm (od) purchased from Chromatographie Service GmbH
(Langerwehe, Germany)). Samples were injected electrokinetically by applying a voltage of
−6 kV for 30 s. Finally, analytes were separated by applying a separation voltage of−20 kV,
and detected by UV at 260 nm. The IC50 values were determined by nonlinear curve
fitting using the GraphPad Prism software 7.0. The mechanism of inhibition of human
NPP1 was determined by employing different concentrations of the inhibitor (0, 10, 30 and
60 nM) vs. five different substrate concentrations ranging from 62 to 800 µM ATP. The assay
procedure and operation conditions were the same as described above. The experiments
were conducted two times, each in triplicates. A Lineweaver–Burk was calculated using
GraphPad Prism 7.0 for predicting the inhibition type of the inhibitor.
3.3. NPP3 Assay
Recombinant soluble human NPP3 was obtained as previously described [47]. Com-
pounds 5–8 were screened at a concentration of 20,000 ng/mL vs. 400 µM p-Nph-5′-TMP to
study a potential inhibition of NPP3, using a colorimetric assay as previously described [38].
Soluble, purified human NPP3 was diluted in the assay buffer (50 mM TRIS HCl, 2 mM
CaCl2 and 0.2 mM ZnCl2 pH 9.00), and 0.45 µg of enzyme per vial was used. The mixture
was incubated for 30 min at 37 ◦C, and the reactions were subsequently terminated by
adding 20 µL of 1.0 N NaOH. The assay is based on the enzymatic ester hydrolysis of
p-Nph-5′-TMP that results in the formation of p-nitrophenolate. The absorption maximum
was measured at 400 nm using a BMG PheraStar FS plate reader (BMG Labtech GmbH,
Ortenberg, Germany). Each analysis was repeated three times in triplicate measurements.
3.4. NPP4 Assay
Recombinant human soluble NPP4 was obtained as previously described [48]. Screen-
ing of the test compounds 5–8 was performed at a concentration of 20,000 ng/mL versus
20 µM of Ap4A as a substrate employing a previously described luminescence-based
assay [48]. The assay buffer consisted of 10 mM HEPES, 1 mM MgCl2 and 2 mM CaCl2
(pH 8.0). The enzyme reaction was started by adding 0.14 µg of human purified NPP4 to
the reaction mixture which was incubated at 37 ◦C for 60 min. The released product, ATP,
was quantified using the luciferin–luciferase reaction. The firefly luciferase reacts with
D-luciferin in the presence of the formed ATP and Mg2+, which act as cofactors. The re-
sulting luminescence correlates to the enzyme activity. It was measured at 560 nm using a
microplate reader (BMG PheraStar, Labtech GmbH, Ortenberg, Baden-Württemberg, Ger-
many). Three independent experiments were performed, each in duplicates with positive
and negative controls studied in parallel.
3.5. NTPDase Assays
Human NTPDases (subtypes 1, 2, 3 and 8) were recombinantly expressed as previously
described and cell membrane preparations overexpressing one of the NTPDase subtypes
were used for the experiments according to described procedures [46]. For monitoring
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the inhibitory activity of the compounds at the NTPDases two different assay system
were utilized. The malachite green assay was used for the determination of NTPDase1
(CD39) concentration–inhibition curves with compound 5–7 and for the determination of
the inhibition type of compound 7. The CE-based assay was utilized for selectivity studies
of compound 5–8 at NTPDase2, NTPDase3 and NTPDase8, and for the determination of
concentration–inhibition curves for compound 8 at human CD39. The test compounds
were investigated at 20,000 ng/mL for initial screening, and subsequently at different
concentrations for obtaining concentration–inhibition curves. The enzyme amounts were
selected after enzymatic titration and adjusted to ensure a conversion rate of 10–20%;
for NTPDase1 assays, 0.1 µg of human umbilical cord membrane preparation [49,50]
was employed per vial, for NTPDase2 assays, 0.07 µg of recombinant enzyme was used,
for NTPDase3 assays, 0.45 µg of enzyme was employed and for NTPDase8 assays, 0.52 µg
of enzyme was utilized. Human NTPDase1, -2, -3 and -8 were expressed as previously
described [49,50]. When the malachite assay was used, the reaction was initiated by the
addition of 50 µM ATP (Km (NTPDase1) = 17 µM) [50]. The reaction buffer consisted of
10 mM HEPES, 2 mM CaCl2 and 1 mM MgCl2, pH 7.4. The enzyme reaction mixture
was incubated at 37 ◦C for 15 min. The released phosphate was quantified by adding
malachite-green and molybdate reagents, incubating for 20 min at room temperature,
and measuring the UV-absorption at 600 nm [51]. The prediction of the mechanism
of inhibition at human NTPDase1 was determined for compound 7 as a representative
example employing different concentrations of the investigated inhibitor (0, 6, 16 and
53 nM of 7) vs. five different substrate concentrations of ATP (from 5 to 200 µM). The assay
procedure and operation conditions were the same as described above. A Lineweaver–Burk
plot was calculated using GraphPad Prism 7.0 for predicting the inhibition type of the
compound. In the CE assay, the selected substrate concentration of ATP was 100 µM for
human NTPDase2, -3 and -8. The reaction buffer was the same as for NTPDase1 described
above. The mixtures of enzyme with the substrate and test compound were incubated
at 37 ◦C for 30 min, and the enzymatic reaction was stopped by heating it for 10 min at
95 ◦C. The released products were separated by capillary electrophoresis and quantified by
their UV-absorption at 260 nm in the presence of ADP and AMP as external standards as
previously described [48]. Positive and negative controls were studied in parallel.
3.6. CD73 Assay
Soluble human CD73 was recombinantly expressed and purified as described [52],
and the assays were performed according to a described procedure [53]. The enzymatic
reaction was performed by mixing 0.36 ng of human CD73 [52], with the test com-
pound (20,000 ng/mL) in the assay buffer (25 mM Tris, 140 mM sodium chloride and
25 mM sodium dihydrogenphosphate, pH 7.4), and 5 µM of [2,8-3H]AMP (specific ac-
tivity 7.4 × 108 Bq/mmol, 20 mCi/mmol, American Radio-labeled Chemicals, MO, USA,
distributed by Hartmann Analytic, Germany) was added. The enzymatic reaction was per-
formed for 25 min at 37 ◦C in a shaking water bath. Then, 500 µL of cold precipitation buffer
(100 mM lanthanum chloride and 100 mM sodium acetate, pH 4.00) was added to stop the
reaction and to facilitate precipitation of free phosphate and unconverted [2,8-3H]AMP. Af-
ter the precipitation was completed (after at least 30 min on ice), the mixture was separated
by filtration through GF/B glass fiber filters using a cell harvester (M-48, Brandel, MD,
USA). After washing each reaction vial three times with 400 µL of cold (4 ◦C) demineralized
water, 5 mL of the scintillation cocktail (ULTIMA Gold XR, PerkinElmer, MA, USA) was
added, and the radioactivity was measured by scintillation counting (TRICARB 2900 TR,
Packard/PerkinElmer; counting efficacy: 49–52%). Positive and negative controls were
tested in parallel.
3.7. Experiments on U87 Glioblastoma Cells
U87 glioblastoma cells were grown in cell culture flasks until reaching a confluent cell
layer. Cells were cultivated at 37 ◦C and 5% CO2 in Dulbecco’s modified Eagle medium
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(DMEM) with additions of 10% FCS, 1% penicillin/streptomycin and 1% L-glutamine.
The cells were rinsed with phosphate-buffered saline (PBS) and detached with ethylene-
diaminetetraacetic acid (EDTA). Thereafter, they were counted in a cell counter (CASY®
1 Model TT, Schärfe System GmbH, Reutlingen, Germany), then rinsed three times with PBS
before they were resuspended in Krebs-HEPES buffer at a concentration of 1×106 cells/mL
per well [54]. Cells (1 mL of a cell suspension containing 106 cells) were then pipetted
into each well of a 24-well plate (Sarstedt AG, Nümbrecht, Germany). Subsequently, the
cells were pretreated with dipyridamole (20 µM) for 30 min to block nucleoside transport.
Adenosine deaminase (ADA) activity was inhibited by the addition of 1 µM of the inhibitor
EHNA, which was added to each sample, and controls [4]. Thereafter, inhibitor 7 was
added, and the samples were incubated with 300 µM of ATP for 3 h. Then, an aliquot of
230 µL of solution from each vial was transferred to 1.5 mL Eppendorf tubes, and heated at
95 ◦C for 10 min to inactivate the enzymes in order to avoid further nucleotide degrada-
tion. Before performing capillary electrophoresis (CE) measurements, the samples were
centrifuged at 600 × g to remove insoluble material like cell debris from the supernatant.
Until CE measurement, the supernatants were stored at −20 ◦C. Nucleotides (ATP, ADP,
AMP and cAMP) and nucleosides (adenosine, inosine and uridine), which were also used
as standards to monitor efficient separation by CE, were dissolved in Krebs-HEPES buffer
at a concentration of 10 µM [54] and stored at −20 ◦C as well. For analysis of the formed
products, CE measurements were performed according to published procedures [55].
4. Conclusions
In conclusion, we identified sulfopolysaccharides isolated from sea algae to act as
extremely potent, noncompetitive inhibitors of the ectonucleotidases NPP1 and CD39
with somewhat higher inhibitory potency against NPP1. Both of these enzymes catalyze
the hydrolysis of proinflammatory, antiproliferative ATP yielding, in concert with the
AMP-hydrolyzing ectoenzyme CD73, adenosine, which displays immunosuppressive
and tumor-promoting activities. In fact, we observed reduced formation of adenosine in
human glioblastoma U87 cells treated with a representative example of the investigated
sulfopolysaccharides. These effects might explain or at least contribute to the previously
observed anticancer effects of sulfated algae polysaccharides from sea weeds, which were
shown to be non-toxic and well tolerated by humans. The sulfate groups are believed to
be essential for their ectonucleotidase-inhibitory effects because other negatively charged
compounds, e.g., some polyoxometalates, can also inhibit these ATP-hydrolyzing enzymes
with high potency. The substrate ATP itself is also a negatively charged compound, and the
enzymes may therefore preferably recognize negatively charged molecules. While ATP
would subsequently be guided to the substrate binding pocket, the large anionic polymers
and cluster compounds likely remain attached to the initial recognition site at the surface of
the enzymes showing allosteric inhibition. In future studies, we plan to investigate the role
of the sulfate groups on the seaweed polysaccharides for their enzyme-inhibitory potency
by investigating derivatives without or with lower degrees of sulfation.
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Ap4A diadenosine tetraphosphate
CD cluster of differentiation
CE capillary electrophoresis
CHES N-cyclohexyl-2-aminoethanesulfonic acid
CD39 nucleoside triphosphate diphosphohydrolase-1
CD73 ecto-5′-nucleotidase
DAD diode array detector




NTPDase1 nucleoside triphosphate diphosphohydrolase-1
NPP1 nucleotide pyrophosphatase/phosphodiesterase-1 (CD203a)
pIC50 negative log of the half-maximal inhibitory concentration
PBS phosphate-buffered saline
pNP-TMP p-nitrophenyl thymidine 5-monophosphate
PSB Pharmaceutical Sciences Bonn
SDS sodium dodecylsulfate
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